What is the recommended initiation and titration protocol for sacubitril/valsartan in a patient with heart failure with reduced ejection fraction already on a stable ACE inhibitor or ARB?

Sacubitril/Valsartan Initiation and Titration in HFrEF Patients on Stable ACE Inhibitor or ARB

For patients with HFrEF already on a stable ACE inhibitor or ARB, switch to sacubitril/valsartan with a mandatory 36-hour washout period after stopping the ACE inhibitor (no washout needed for ARBs), starting at 49/51 mg twice daily if on high-dose ACEI/ARB (≥enalapril 10 mg daily or valsartan 160 mg daily equivalent), or 24/26 mg twice daily if on low-to-medium doses, then titrate every 2-4 weeks to the target dose of 97/103 mg twice daily. 1, 2

Critical Washout Period

• Strictly observe a 36-hour washout period when switching from an ACE inhibitor to sacubitril/valsartan to avoid angioedema 1, 2
• No washout period is required when switching from an ARB 1
• This is a contraindication, not merely a precaution—concomitant use with ACE inhibitors is absolutely prohibited 2

Initial Dosing Based on Prior ACEI/ARB Dose

The starting dose depends on the equivalent dose of your patient's current ACEI or ARB: 1

• High-dose ACEI (≥enalapril 10 mg daily equivalent): Start sacubitril/valsartan 49/51 mg twice daily 1
• High-dose ARB (≥valsartan 160 mg daily equivalent): Start sacubitril/valsartan 49/51 mg twice daily 1
• Low- or medium-dose ACEI (<enalapril 10 mg daily equivalent): Start sacubitril/valsartan 24/26 mg twice daily 1, 2
• Low- or medium-dose ARB (<valsartan 160 mg daily equivalent): Start sacubitril/valsartan 24/26 mg twice daily 1, 2

Titration Protocol

Double the dose every 2-4 weeks as tolerated, targeting 97/103 mg twice daily: 1, 2

• Standard titration schedule: 24/26 mg → 49/51 mg → 97/103 mg twice daily 1
• Both condensed (3-week) and conservative (6-week) titration approaches are similarly tolerated 1, 3
• However, gradual titration (every 2-4 weeks) maximizes attainment of target dose, particularly in patients previously on low-dose ACEI/ARB 1, 3

Monitoring Requirements

Monitor blood pressure, electrolytes (especially potassium), and renal function: 1

• Check at 2-3 days after initiation 1
• Recheck after each dose increment 1
• Monitor monthly for the first 3 months, then at regular intervals 1

Special Populations Requiring Dose Adjustment

Start at 24/26 mg twice daily in these populations regardless of prior ACEI/ARB dose: 1, 2

• Severe renal impairment (eGFR <30 mL/min/1.73 m²) 1, 2
• Moderate hepatic impairment (Child-Pugh Class B) 1, 2
• Elderly patients (age ≥75 years) 1
• ACEI/ARB-naïve patients 1

Managing Hypotension

Sacubitril/valsartan exerts more pronounced blood pressure effects than ACEIs/ARBs: 1

• In patients with borderline blood pressure (systolic BP ≤100 mmHg), careful administration and close follow-up are essential 1
• In non-congested patients with stable clinical profiles, empirically reduce loop diuretic doses modestly to mitigate hypotensive effects 1
• Ensure patients are not volume-depleted at initiation, as up to 25% may develop hypotension 1
• Asymptomatic or mildly symptomatic low blood pressure should NOT prevent initiation or uptitration 4
• The majority of patients (>80%) with systolic BP ≥100 mmHg can achieve target dose with gradual titration 5

Common Pitfalls to Avoid

Do not delay switching to sacubitril/valsartan due to lack of aldosterone antagonist therapy—there is no requirement for prior aldosterone antagonist use 1

Do not continue ACE inhibitor within 36 hours of starting sacubitril/valsartan—this significantly increases angioedema risk 1, 2

Do not start at 49/51 mg in patients on low-dose ACEI/ARB—this increases risk of hypotension and reduces likelihood of achieving target dose 1, 3

Do not withhold therapy in patients with NYHA Class IV symptoms—sacubitril/valsartan remains indicated, though data are more limited 1

Alternative Approach: Direct to Target Dose

Recent evidence suggests patients already on high-dose ACEI/ARB (≥enalapril 10 mg twice daily equivalent) can be switched directly to maximum-dose sacubitril/valsartan (97/103 mg twice daily) safely: 6

• In a prospective study, 86% of patients on target-dose ACEI/ARB maintained maximum-dose sacubitril/valsartan at 12 months 6
• Only 14% discontinued and 6% required dose reduction 6
• No angioedema occurred and no hospitalizations within first 14 days 6
• However, 26% developed symptomatic hypotension 6

This approach reduces titration steps but requires careful patient selection and close monitoring—the standard gradual approach remains preferred in most guidelines 1

Expected Outcomes

Target dose achievement varies in real-world practice: 7, 8

• In clinical practice, 27-77% of patients achieve target dose within 6-12 months 7, 8
• Main barriers include slower uptitration than trials, hypotension, and patient non-compliance 7
• Advanced age and lower systolic blood pressure predict failure to reach target dose 8

Clinical benefits occur even with submaximal doses, but target dose provides optimal mortality and hospitalization reduction 1, 9